Cancer discovery, 2016-09, Vol.6 (9), p.949-952
2016
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Developing EZH2-Targeted Therapy for Lung Cancer
- Ist Teil von
- Cancer discovery, 2016-09, Vol.6 (9), p.949-952
- Ort / Verlag
- United States
- Erscheinungsjahr
- 2016
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2159-8274eISSN: 2159-8290DOI: 10.1158/2159-8290.cd-16-0800Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5012289
- Format
- –
- Schlagworte
- Animals, Antineoplastic Agents - chemistry, Antineoplastic Agents - pharmacology, Antineoplastic Agents - therapeutic use, Disease Models, Animal, Drug Discovery, Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors, Epigenesis, Genetic - drug effects, Humans, Lung Neoplasms - drug therapy, Lung Neoplasms - genetics, Lung Neoplasms - metabolism, Lung Neoplasms - pathology, Mice, Molecular Targeted Therapy, Xenograft Model Antitumor Assays